Table 9.

Variant persistence in HCV patients after treatment QD with 60 mg of DCV by population sequence

Patient	Genotype	Time	RNA (IU/ml)	Substitution(s) (% frequency)a				Additional mutation (% frequency)
				M28	Q30	L31	Y93
M	1a	T0	1.7E+07	V (∼40%)	R (∼10%)
		Day 14	4.9E+06	A (∼5%), T (∼5%), V (∼5%)	H (∼95%), R (∼5%)		H (∼95%)
		Day 15	7.1E+06	A (∼5%), T (∼5%), V (∼5%)	H (∼95%), R (∼5%)		H (∼95%)
		Day 21	1.0E+07	A (∼5%), T (∼5%), V (∼5%)	H (∼95%), R (∼5%)		H (∼95%)
		Day 28	1.3E+07	A (∼5%), T (∼5%), V (∼5%)	H (∼95%), R (∼5%)		H (∼95%)
		Day 42	1.6E+07	A (∼5%), T (∼5%), V (∼5%)	H (∼90%), R (∼10%)		H (∼90%)
N	1a	T0	1.8E+06	V (∼2.5%)
		Day 14	3.9E+03	A (∼7.5%), T (∼42.5%), V (∼10%)	E (∼45%), K (∼25%), R (∼15%)		N (∼10%)
		Day 15	5.8E+03	T (∼20%)	E (∼45%), H (∼10%), R (∼2.5%)	M (∼5%)	N (∼40%)
		Day 21	5.8E+05	T (∼20%)	E (∼50%), H (∼5%), R (∼10%)	M (∼5%)	N (∼30%)
		Day 28	6.0E+05	T (∼20%)	E (∼60%), H (∼5%), R (∼20%)	M (∼2.5%)	N (∼15%)
		Day 42	9.6E+05	T (∼20%)	E (∼70%), H (∼5%), R (∼20%)	M (∼5%)
		Day 98	1.6E+06	T (∼45%)	E (∼50%), R (∼40%)	M (∼5%)
		Day 182	1.8E+06	T (∼40%)	E (∼60%), R (∼40%)
O	1a	T0	8.9E+06	WT	WT	WT	WT
		Day 14	2.2E+06	T (∼ 5%)	E (∼62.5%), R (∼5%)		N (∼5%)
		Day 15	2.1E+06	T (∼ 5%)	E (∼75%), R (∼10%)	M (∼5%)	N (∼10%)
		Day 21	4.0E+06	T (∼ 5%)	E (∼67.5%), R (∼10%)	M (∼5%)	N (∼5%)
		Day 28	5.1E+06	T (∼ 5%)	E (∼70%), R (∼10%)	M (∼5%)
		Day 42	5.9E+06	T (∼5%)	E (∼70%), R (∼10%)	M (∼5%)
		Day 98	1.3E+07	T (∼10%)	E (∼60%), R (∼15%)	M (∼10%)
		Day 182	3.4E+06	T (∼15%)	E (∼50%), R (∼20%)	M (∼15%)
P	1a	T0	2.4E+07	WT	WT	WT	WT	E62D (∼100%)
		Day 14	4.4E+06		R (∼100%)			E62D (∼100%)
		Day 15	7.9E+06		R (∼100%)			E62D (∼100%)
		Day 21	2.3E+07		R (∼100%)			E62D (∼100%)
		Day 28	3.5E+07		R (∼100%)			E62D (∼100%)
		Day 42	3.6E+07		R (∼100%)			E62D (∼100%)

^aFrequencies are quantitative estimates of variants based on chromatograms from population sequencing (estimated from the average of two PCR products). “WT” indicates consensus with the WT. Data for T0 to day 14 have been reported previously (3, 4).